Skip to main content

Lipid Signaling in Human Diseases

  • Book
  • © 2020

Overview

  • Reviews the current status of the field of lipid signaling focused on translational significance with the prospect to be clinically relevant for human disease
  • The book combines both basic principles and applied agents with clinical significance for lipid cell signaling, phospholipases and lipid kinases, lipid metabolism and trafficking, and bioactive lipids
  • Drug development and novel application ideas are incorporated where possible

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 259)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (14 chapters)

  1. New Roles for Sphingolipid Signaling and Cell Function

  2. Phospholipase D and Mitogen Phosphatidic Acid in Human Disease

  3. Lipid Kinases and Novel Regulatory Pathways

  4. Bioactive Lipids in Health and Disease

  5. Lipids and Membrane Microdomains

  6. Nuclear Trafficking of Lipids

Keywords

About this book

Lipids are an integral part of cell membrane architecture, are intermediaries in cell metabolism, and are involved in transmitting cell signals from hormones, growth factors and nutrients. A number of lipases and phospholipases, lipid kinases, lipid phosphatases, sphingosine kinases, and their reaction products have been implicated in fundamental cellular processes including cell proliferation, division and migration. These enzymes and their products underlie the molecular mechanisms of numerous human diseases, in particular metabolic disease (diabetes), cancer, neurodegenerative disease and cardiovascular disease.

Over the last decade, studies have advanced to the point that a number of inhibitors for these enzymes have been developed to attempt to ameliorate these conditions; some of the inhibitors are currently in human clinical trial. The need for this book is to review the current status of this field and the prospect for the inhibitors to be clinically important.

 

Editors and Affiliations

  • Department of Biochemistry and Molecular Biology, Wright State University, Dayton, USA

    Julian Gomez-Cambronero

  • Department of Pharmacological Sciences, Stony Brook University, Stony Brook, USA

    Michael A. Frohman

Bibliographic Information

Publish with us